<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30243153</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1768-3254</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>158</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of medicinal chemistry</Title>                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.</ArticleTitle>            <Pagination>                <MedlinePgn>493-501</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(18)30819-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2018.09.047</ELocationID>            <Abstract>                <AbstractText>To explore antitumor agents with potent efficacy and low toxicity, scutellarein derivatives with benzoic acid mustard (10a-c, 11a-c and 13a-c) were designed and synthesized. The antiproliferative activities of the target derivatives against A549, MCF-7 and Bel-7402 cancer cell lines were tested. Compound 10a showed the strongest potency with an IC<sub>50</sub> value of 1.50 μM against MCF-7 cell line, and displayed low toxicity against human liver L-O2 normal cells (IC<sub>50</sub> &gt; 50 μM), showing specificity between normal and malignant cells. The mechanism studies revealed that 10a could induce apoptosis in MCF-7 cells, arrest MCF-7 cell cycle at the G1 phase and cause mitochondrial dysfunction in a concentration-dependant manner. Furthermore, the enhanced expression of the pro-apoptotic proteins caspase-9, caspase-3, Bax and cytochrome c, and the reduced expression of the anti-apoptotic protein Bcl-2 confirmed that 10a induced the intrinsic apoptosis pathway in MCF-7 cells. The potent antiproliferative activity and good selectivity guaranteed 10a a lead compound for the further development into anticancer therapeutics, especially for breast cancer.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Tong</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Yantai Valiant Pharmaceutical Co., Ltd., 60 Taiyuan Road, Dajijia Industrial Park, YEDA Yantai, 264006, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Mingying</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xu</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Kangyuan Road, Lianyungang, 222001, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Keguang</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, and School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Raod, Guilin, 541004, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gao</LastName>                    <ForeName>Xiang</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Zhanlin</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bai</LastName>                    <ForeName>Jiao</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hua</LastName>                    <ForeName>Huiming</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Dahong</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China. Electronic address: lidahong0203@163.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Eur J Med Chem</MedlineTA>            <NlmUniqueID>0420510</NlmUniqueID>            <ISSNLinking>0223-5234</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>7V515PI7F6</RegistryNumber>                <NameOfSubstance UI="D047310">Apigenin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>8SKN0B0MIM</RegistryNumber>                <NameOfSubstance UI="D019817">Benzoic Acid</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P460GTI853</RegistryNumber>                <NameOfSubstance UI="C458179">scutellarein</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047310" MajorTopicYN="N">Apigenin</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019817" MajorTopicYN="N">Benzoic Acid</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Antiproliferative activity</Keyword>            <Keyword MajorTopicYN="N">Benzoic acid mustard</Keyword>            <Keyword MajorTopicYN="N">Scutellarein</Keyword>            <Keyword MajorTopicYN="N">Selectivity</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30243153</ArticleId>            <ArticleId IdType="pii">S0223-5234(18)30819-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejmech.2018.09.047</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>